Cite
Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants
MLA
John M Findlay, et al. “Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.” Molecular Diagnosis & Therapy, vol. 24, no. 3, Apr. 2020, pp. 339–49. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b5ed78feffd224e578c3680a28bb8b10&authtype=sso&custid=ns315887.
APA
John M Findlay, Gerald Martin, Jean-Francois Laes, Matthew Smith, Gary Middleton, Andrew D Beggs, Valerie Pestinger, Toju Sillo, & Phillipe Taniere. (2020). Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants. Molecular Diagnosis & Therapy, 24(3), 339–349.
Chicago
John M Findlay, Gerald Martin, Jean-Francois Laes, Matthew Smith, Gary Middleton, Andrew D Beggs, Valerie Pestinger, Toju Sillo, and Phillipe Taniere. 2020. “Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.” Molecular Diagnosis & Therapy 24 (3): 339–49. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b5ed78feffd224e578c3680a28bb8b10&authtype=sso&custid=ns315887.